Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2023 Financial Results on May 10, 2023
Sera Prognostics (NASDAQ: SERA), focused on enhancing maternal and neonatal health through innovative pregnancy biomarker information, will report its first-quarter fiscal 2023 financial results on May 10, 2023. The report will follow a conference call at 5:00 PM ET, where operational highlights and financial results will be discussed. The PreTRM® Test, developed by Sera, predicts preterm birth risk, allowing for early interventions and potentially reducing healthcare costs associated with complications. The firm emphasizes its commitment to improving pregnancy care and health outcomes for mothers and newborns, while navigating various risks related to its revenue reliance on the PreTRM Test and potential market competition.
- Upcoming financial results may provide insights on growth and operational success.
- Focus on innovative diagnostics like the PreTRM® Test enhances market position.
- Commitment to reducing healthcare costs associated with pregnancy complications.
- Dependence on the PreTRM Test for substantially all revenue raises risk.
- Future growth may be hampered by market competition and acceptance issues.
- Potential need for capital raises due to net losses and cash generation challenges.
Conference Call Details:
US domestic callers: (866) 218-2405
International callers: (412) 902-6607
Webcast Registration Link: https://app.webinar.net/YPlZL7A5y82
Live audio of the webcast will be available online from the Investors page of the Company's website at www.seraprognostics.com. The webcast will be archived on the Investors page and will be available for one year.
About
About Preterm Birth
Preterm birth is defined as any birth before 37 weeks' gestation and is the leading cause of illness and death in newborns. The 2022 March of Dimes Report Card shows that, for the last four consecutive years, more than one in ten infants is born prematurely. Prematurity is associated with a significantly increased risk of major long-term medical complications, including learning disabilities, cerebral palsy, chronic respiratory illness, intellectual disability, seizures, and vision and hearing loss, and can generate significant costs throughout the lives of affected children. The annual health care costs to manage short- and long-term complications of prematurity in the United States were estimated to be approximately
About the PreTRM® Test
The PreTRM® Test is the only broadly validated, commercially available blood-based biomarker test that provides an early, accurate and individualized risk prediction for spontaneous preterm birth in asymptomatic singleton pregnancies. The PreTRM® Test measures and analyzes proteins in the blood that are highly predictive of preterm birth. The PreTRM® Test permits physicians to identify, during the weeks 18 through 20 of pregnancy, which women are at increased risk for preterm birth and its complications, enabling more informed, personalized clinical decisions based on each woman's individual risk. The PreTRM® Test is ordered by a medical professional.
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the date, time and content of the Company's quarterly earnings release and conference call; and the company's strategic directives under the caption "About
View original content to download multimedia:https://www.prnewswire.com/news-releases/sera-prognostics-announces-conference-call-and-webcast-of-first-quarter-fiscal-year-2023-financial-results-on-may-10-2023-301808839.html
SOURCE
FAQ
When will Sera Prognostics report its Q1 financial results for 2023?
What is the PreTRM Test offered by Sera Prognostics?
What are the risks mentioned by Sera Prognostics in their press release?
What is Sera Prognostics' mission?